Alpha Tau Medical (DRTS) Cost of Revenue (2021 - 2026)

Alpha Tau Medical (DRTS) has reported Cost of Revenue for 6 consecutive years, with $241000.0 the latest figure, recorded in Q1 2026.

• Quarterly Cost of Revenue fell 47.49% year-over-year to $241000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (down 27.82% YoY) and the FY2025 annual result came in at $1.9 million, down 20.82% from the prior year.
• Cost of Revenue retreated to $241000.0 in Q1 2026 per DRTS's latest filing, from $452000.0 in the prior quarter.
• Over the last five years, Cost of Revenue for DRTS reached as high as $687000.0 in Q4 2024 and fell as low as $121000.0 in Q2 2022.
• A 5-year average of $432235.3 and a median of $459000.0 in 2025 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2023 — Cost of Revenue jumped 329.75% — and 2026, when it tumbled 47.49%.
• Year by year, Cost of Revenue stood at $397000.0 in 2022, then advanced by 13.85% to $452000.0 in 2023, then surged by 51.99% to $687000.0 in 2024, then sank by 34.21% to $452000.0 in 2025, then plunged by 46.68% to $241000.0 in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $241000.0, $452000.0, and $490000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.